Hepatorenal syndrome type 1 and bacterial infection: A catastrophic association in patients with cirrhosis

Hepatology

Volumn 59, Issue 4, 2014, Pages 1239-1241

  Salerno, Francesco ^a   Monti, Valentina ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; BILIRUBIN; TERLIPRESSIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; DRUG EFFICACY; GLOMERULUS FILTRATION; HEPATORENAL SYNDROME; HOSPITAL INFECTION; HUMAN; KIDNEY INJURY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL; SHORT TERM SURVIVAL; TREATMENT FAILURE;

BACTERIAL INFECTIONS; FEMALE; HEPATORENAL SYNDROME; HUMANS; KIDNEY; LIVER CIRRHOSIS; MALE;

EID: 84896493707     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27015     Document Type: Article

References (12)

1. Salerno F, Gerbes A, Ginés P, Wong F, Arroyo V. Hepatorenal syndrome in cirrhosis. Gut 2007;56;1310-1318.
2. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426-1437.
3. Arroyo V, Ginés P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and iagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-176.
4. Guevara M, Ginès P, Fernández-Esparrach G, Sort P, Salmerón JM, Jiménez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41.
5. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007;45:223-229.
6. Sort P, Navasa M, Arroyo V, Aldeguer J, Planas R, Ruiz del Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.
7. Guevara M, Terra C, Nazar A, Solà E, Fernández J, Pavesi M, et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol 2012;57:759-765.
8. Barreto R, Fagundes C, Guevara M, Solà E, Pereira G, Rodrìguez E, et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis. Natural history, outcome, of kidney function and survival. Hepatology 2014;59:1505-1513.
9. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-724.
10. Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-824.
11. Sydnor ERM, Perl TM. Hospital epidemiology and Infection control in acute-care settings. Clin Microbiol Rev 2011;24:141-173.
12. Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010;8:979-985.